Introduction
Reversible protein phosphorylation is a major mechanism regulating the physiology of plant and animal cells. Steady-state phosphorylation reflects the balance between protein kinases and phosphatases. Protein phosphatase type-1 (PP1) is one of the major eukaryotic serine/threonine phosphatases, which regulates many biological processes, including synaptic plasticity, cell cycle, gene transcription, and metabolism. 1 The functional diversity of PP1 is accomplished by the association of its catalytic subunit with more than a hundred endogenous regulatory subunits. 2 One of the longest recognized regulators of PP1 is inhibitor-1 (I-1) that selectively and potently inhibits the PP1 catalytic subunit (PP1c, IC 50 PP1-sensitive phosphoproteins, I-1 appears to specifically affect dephosphorylation of phospholamban (PLB) and ryanodine receptors (RyR) regulating sarcoplasmic reticulum Ca 2+ uptake and release, respectively. 7, 8 I-1 expression and phosphorylation was shown to be decreased in heart failure similar to the downregulation of β 1 -adrenoceptors, 8, 9 suggesting that it contributes to the well-known desensitization phenomenon of β-adrenergic signaling in failing hearts and failing cardiomyocytes. Whereas some investigators provided evidence that restoration of high I-1 levels has beneficial effects under cardiac stress conditions, 10 we observed that genetic ablation of I-1 protected mice against acute and chronic catecholamine stimulation without affecting heart rate. 11 Conversely, overexpression of a truncated constitutively active form of I-1 improved cardiac output in the short term but exaggerated contractile dysfunction after chronic catecholamine infusion as well as spontaneously in aging mice. 12 These findings suggest that pharmacological I-1 blockade may represent a new strategy in treating heart failure.
Current assays for measuring PP1 activity, either as free catalytic subunit or as holoenzyme, are based on PP1c-mediated dephosphorylation of radioactively labeled phosphoproteins, particularly phosphorylase a. 3, 13 Those assays are relatively expensive, require facilities for radioactive work, and are not suitable for high-throughput drug screening. The general preference for nonradioactive high-throughput assays has provided an immense challenge for many investigators. Parker et al. 14 and Rodems et al. 15 presented a fluorescence polarization (FP)-based assay and a fluorescence resonance energy transfer (FRET)-based assay, respectively, for the detection of kinase and phosphatase activities. More recently, a high-throughput phosphatase assay was described using rhodamine 110-modified phosphopeptide substrates. 16 Although each of these systems is amenable for high-throughput screening (HTS), higher selectivity and reliability are still required, particularly for assessment of serine/threonine phosphatase activities. Moreover, the available phosphatase assays monitor the activity of the catalytic subunit of phosphatases alone, whereas serine/threonine phosphatases normally exist in a nonmonomeric form. Thus, assays are needed that are composed of both catalytic and regulatory subunits.
Here we developed a nonradioactive, reliable, and costefficient phosphatase-inhibitor assay and screened several thousand compounds for their effect on PP1c-I-1 interactions. By employing a chromogenic and a fluorogenic substrate we identified a small peptide that potently interfered with the inhibitory effect of I-1 P on PP1c.
Materials and Methods

Colorimetric and Fluorescence Phosphatase Assays
The colorimetric assays were performed in transparent flatbottom 96-well plates (Sarstedt AG, Nümbrecht, Germany) in a final volume of 220 µL. ) was added to the wells. The reactions were mixed by addition of 160 µL assay buffer and initiated by addition of 20 µL pNPP stock solution, yielding a final concentration of 4.5 mM. The substrate saturation curve was determined in the presence of 1 U PP1c at different substrate concentrations (0.5-50 mM). The absorptions were measured immediately for 30 min at 30 °C using a TECAN Safire 2 (TECAN, Männedorf, Switzerland) multiplate reader and analyzed with the Magellan software 5.03 (TECAN). The gradient of optical density (ΔOD/min) was considered as phosphatase activity for each sample.
The fluorescence assays were carried out in black flatbottom 384-well plates (Greiner Bio-One, Frickenhausen, Germany) in a final volume of 100 µL. The fluorogenic substrate, DiFMUP (kind gift from Dr. Lars Kattner, Endotherm, Saarbruecken, Germany), was prepared in 50 mM Tris-HCl (pH 7.0) at a 10-mM stock solution and stored at −20 °C. Recombinant PP1c from rabbit skeletal muscle (specific activity 25 U/µg protein; New England Biolabs, Ipswich, MA; 1 unit definition is the amount of enzyme that hydrolyzes 1 nmol pNPP in 1 min at 30 °C) was prepared at 0.5 to 16 mU/well in 50 µL enzyme dilution buffer. Reactions were started by addition of 50 µL assay buffer containing DiFMUP (100 µM), resulting in a final concentration of 50 µM. Substrate saturation curve was obtained using a constant concentration of recombinant PP1c (2 mU) with different concentrations of DiFMUP (5-200 µM O in a stock concentration of 10 mM, and aliquots were stored at −80 °C.
PKA Phosphorylation/Thiophosphorylation of Recombinant I-1 Protein
I-1 complementary DNA (cDNA) of mouse heart subcloned in pGEX-2T expression vector, provided by Dr. Katrin Wittköpper, was used to express I-1 as a fusion protein with glutathione-S-transferase (GST) as described earlier. 7 The recombinant I-1 protein was in vitro phosphorylated at Thr35 using the purified catalytic subunit of PKA (PKAc, specific activity ~10 U/µg protein; Sigma-Aldrich) to become activated. Phosphorylation/thiophosphorylation of I-1 protein was performed using a protocol described by Endo et al. 17 The phosphorylation reaction was carried out in phosphatebuffered saline (PBS) at pH 7.4, containing 6 mM MgCl The reactions were terminated by incubating at 95 °C for 5 to 10 min and desalted in the enzyme dilution buffer using Amicon, 10K devices (Millipore, Billerica, MA) according to the manufacturer's guideline. Thiophosphorylation of the I-1 protein was performed essentially as described above except that ATP was substituted with 0.3 mM ATP-γ-S (adenosine 5′-[3-thiotriphosphate]), which is a nonhydrolyzable ATP analogue. Instead of 6 mM, 2 mM MgCl 2 was used and the reaction was incubated at 30 °C for 24 h. The phosphorylated/ thiophosphorylated proteins were stored at −80 °C.
Western Blot Analysis
Recombinant I-1 proteins before and after phosphorylation/ thiophosphorylation were prepared with the buffer containing 10 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 100 mM DTT, and 0.01% bromophenol blue; heated at 95 °C for 5 min; and loaded on a 12% SDS-containing polyacrylamide gel. The SDS extracts were blotted on nitrocellulose membranes (Protran, Schleicher & Schüll, Dassel, Germany) for 90 min on ice with a constant current of 300 mA. The membranes were incubated with polyclonal antibodies raised against I-1 (1:1000, produced in house as described previously 7 ) and phospho-DARPP-32 (1:1000; Cell Signaling Technology, Danvers, MA) for detection of I-1 protein or phosphorylated/thiophosphorylated level, respectively.
Radioactive Phosphatase Assay
The activities of recombinant PP1c (Sigma-Aldrich) in the presence of I-1 P and I-1 SPRKIQFTV or I-1 PHLDPEAAEQI were determined using [ 32 P]-phosphorylase a as substrate as described previously. 7 After preincubation of PP1c-I-1 P complex (0.1 U PP1c + 3 nM I-1 P ) with the peptide for 20 min at 30 °C, 5 mg/mL [ 32 P]-phosphorylase a was added and the reaction was carried out for 20 min and then terminated by the addition of 50% trichloroacetic acid (TCA). After centrifugation, aliquots of the supernatant were counted in a liquid scintillation counter (Canberra Packard, Meriden, CT).
PP1c-I-1 P High-Throughput Screening
Screening of a library of drug and lead-like small molecules from the ChemBionet library 18 in a high-throughput format was performed by the facilities of European ScreeningPort, GmbH (Hamburg, Germany). The reactions were carried out in 384-well plates in a final volume of 10 µL. The PP1c-I-1 P mixture was prepared freshly. The components (PP1c and I-1 P ) at 43.2 pM and 60 nM, respectively, were preincubated for 10 min. A PP1c mixture containing only PP1c was prepared as a control for phosphatase activity in the absence of I-1 P . "Assay-ready" plates were produced from compound library stocks (10 mM in 100% DMSO) using acoustic dispensing (Echo 550; Labcyte, Sunnyvale, CA) at 4 to 6 h prior to screening. To each well, 5 µL of the PP1c-I-1 P mixture was added and compounds preincubated with the mixture for 15 min at 30 °C. The PP1c activity was initiated by addition of 5 µL assay buffer containing DiFMUP (10 µM stock concentration). Final reaction concentrations were 21.6 pM (2 mU/well) PP1c, 30 nM I-1 P , 5 µM DiFMUP, 20 µM test compounds, and 0.5% DMSO. The lidded plates were then incubated at 30 min incubation at 30 °C. The fluorescence intensity (excitation 385 nm, emission 490 nm) was then measured for a further 30 min in kinetic mode (1 read per minute) on an EnVision multimode reader (PerkinElmer, Hamburg, Germany). Time-series data were subject to linear regression analysis (EnVision software) and plate-level statistics (Z′) calculated in the IctivityBase software (IDBS, Guildford, UK). Plates with a Z′ value lower than 0.3 were excluded.
Results
Colorimetric PP1c-I-1 P Assay System
In a first step, pNPP was employed as a chromogenic substrate. Originally, pNPP had been used in conjunction with alkaline phosphatases due to its intense hydrolysis in basic milieu, but it is also feasible for the determination of acidic phosphatases, tyrosine phosphatases, and serine/threonine phosphatases. 19 The activity of recombinant PP1c (0.4-1.6 U/well) was monitored in the presence of 4.5 mM pNPP (Fig. 1A) . The optical density (OD) increased linearly with increasing phosphatase concentrations. PP1c at 1 U/well was used for further experiments. We observed a linear increase in OD between 5 and 30 min (Fig. 1B) . Substrate concentration-dependency was measured with 1 U PP1c and a 30-min incubation and showed a typical MichaelisMenten saturation curve with a calculated K m value of 3 mM (GraphPad Prism 5.02; GraphPad Software, La Jolla, CA) (Fig. 1C) .
Next, we compared the inhibitory effects of various PP1c inhibitors to determine the assay pharmacology. I-2 was used as a selective protein inhibitor of PP1c; calyculin A, OA, and cantharidin were used as nonselective chemical inhibitors of values obtained were consistent with earlier reports. 20 These data indicated the principal feasibility of the colorimetric assay.
To establish a PP1c-I-1 P assay system, we generated recombinant I-1 protein. Since I-1 phosphorylation on Thr35 is essential for its activity against PP1c, I-1 was phosphorylated by PKAc in the presence of ATP. Robust phosphorylation was verified by Western blot with phosphospecific antibodies (Fig. 2E) . However, in the presence of PP1c, the I-1 phosphorylation state completely disappeared during the 5-min incubation period with PP1c. This indicates that recombinant PP1c at the high concentrations used herein was able to dephosphorylate I-1 P . By using the nonhydrolyzable ATP analogue ATP-γ-S instead of ATP (I-1 SP ), we achieved partial resistance against PP1c-mediated dephosphorylation (Fig. 2E) . I-1 SP inhibited PP1c activity with an IC 50 value of 186 nM, whereas nonphosphorylated I-1 was without effect (Fig. 2F) . The observed IC 50 value was ~100-fold higher than values reported for native PP1c and natural substrates (1-2 nM).
3,21
Fluorescence PP1c-I-1 P Assay System
To circumvent the problem of I-1 P -dephosphorylation at the high PP1 concentrations, DiFMUP was used as a fluorogenic substrate. DiFMUP is a derivative of the 4-methylumbelliferyl phosphate (4-MUP) with superior spectral properties to 4-MUP at pH 7.0. 22 At 50 µM DiFMUP and a 30-min incubation, the fluorescence signal increased linearly between 0.5 and 16 mU PP1c/well (Fig. 3A) . At 2 mU PP1c and 50 µM DiFMUP, the assay was linear between 5 and 30 min (Fig. 3B) and showed a substrate concentrationdependency according to a Michaelis-Menten equation with a K m value of 91 µM (Fig. 3C) . The high activity of PP1c against DiFMUP allowed us to use a 500-fold lower amount of PP1c than in the colorimetric assay (2 mU vs. 1U). Under these conditions, the IC 50 values of I-2, calyculin A, and cantharadin were ~30-fold, 8-fold, and ~2-fold, respectively, lower than in the colorimetric assay (Fig.  4A,B,D) , whereas that of OA was similar (Fig. 4C) . I-1 P inhibited the low concentration of recombinant PP1c in the fluorescent assay with an IC 50 value of 14 nM (Fig. 4E) . This value was relatively close to the value obtained with native PP1c using phosphorylase a as substrate (1-2 nM Fig. S1A ). Western blot analysis revealed that a low concentration (4 mU) of both recombinant and native PP1c did not affect I-1 P , whereas a high concentration (1 U) resulted in complete dephosphorylation of I-1 P by recombinant PP1c and ~35% dephosphorylation by native PP1c (Suppl . Fig. S1B ). 
Identification of an I-1 Nonapeptide Interfering with the Effect of I-1 P on PP1c
We hypothesized that a peptide that mimics the region of I-1 that binds to PP1c should interfere with the effect of I-1 P on PP1c and should exert stimulatory effects in our PP1c-I-1 P assay. We therefore designed a nonapeptide derived from the N-terminal domain of I-1 ( 6 SPRKIQFTV 14 ). The peptide contains the KIQF motif, which is essential for I-1 binding to PP1c.
3,17 An 11-residue peptide, containing amino acids following the KIQF motif of I-1 ( 19 PHLDPEAAEQI 29 ), was applied as a control peptide. Both peptides were preincubated at different concentrations with PP1c-I-1 SP or PP1c-I-1 P complexes in the presence of pNPP or DiFMUP, respectively. As expected, I-1 SPRKIQFTV concentration-dependently restored PP1c activity with an EC 50 value of 27 µM and 2.3 µM in the colorimetric and fluorescence assays, respectively (Fig. 5A,B) . In contrast, I-1 PHLDPEAAEQI did not affect the inhibitory effect of I-1 on PP1c activity. The effect of the peptides was further examined in a radioactive assay using [ 32 P]-phosphorylase a as the substrate. Incubation of the PP1c-I-1 P complex (0.1 U PP1c + 3 nM I-1 P ) with 10 µM of I-1 SPRKIQFTV abolished the inhibitory effect of I-1 P on PP1c activity, whereas 10 µM I-1 PHLDPEAAEQI was not effective (Fig. 5C) .
Characterization of the PP1c-I-1 P Assay for HTS
The data above indicated the suitability of both colorimetric and fluorescence assays for the identification of PP1c-I-1 P inhibitors. However, the higher sensitivity of the DiFMUP assay favored its utilization for HTS. We therefore determined the Z′ factor as a measure of the quality and reliability of assays, particularly for HTS. Determination of Z′ factor was performed by monitoring the fluorescence signals of wells containing buffer without enzyme (blank), PP1c (4 mU/well), or PP1c-I-1 P complex (4 mU/well PP1c + 50 nM I-1 P ) for ~60 min. The assay window demonstrated an appropriate signal dynamic between blank, PP1c, and PP1c-I-1 P , which was essential for the detection of compounds with I-1 P -or PP1c-inhibitory effect (Suppl . Fig.  S2A) . Z′ values calculated according to Zhang et al. 23 amounted to 0.84 for blank/PP1c and 0.73 for PP1c/PP1c-I-1 P after a 30-min incubation (Suppl . Fig. S2B ). The assay was sensitive to DMSO at concentrations >1% (v/v) when PP1c was measured alone and to DMSO at >8% (v/v) when PP1c-I-1 P were measured together (Suppl. Fig. S3 ). Maximal DMSO in compound testing was 0.5%. Collectively, these data demonstrate the suitability of the fluorescence assay system for HTS.
A library of 4576 compounds was tested for inhibition of the PP1c-I-1 P interaction by adding them to the PP1c-I-1 P solution. Kinetic measurements were carried out between 30 and 60 min after reaction start (Suppl. Fig. S4 ). Linear regressions were applied to obtain the signal intensities at the time before initiation of the reaction (T = 0; Fig. 6A ). Subsequently, the intensities were normalized to the controls to compare the percentage of convergence relative to the "low control" (PP1c-I-1 P ). Interfering compounds did not converge with the controls. Auto-fluorescent compounds showed a higher baseline, whereas the quenchers demonstrated a lower baseline compared with the "low control" (Fig. 6B) . Compounds with ~100% convergence could be categorized into different groups based on their gradients. Potential I-1 P inhibitors (= hits) were defined as compounds associated with a gradient between the low and high controls. A gradient close to the "high control" (PP1c) would indicate a very high inhibitory effect on I-1 activity. Compounds with a gradient lower than the "low control" would normally be considered PP1c inhibitors (Fig.  6B) . However, OA, used as a positive control for PP1c inhibitors, did not lower the gradient below the "low control" even at relatively high concentrations (Suppl. Fig. S5 ), suggesting that, under the experimental conditions, inhibition by I-1 P was already maximal. Compounds that showed similar gradients as the "low control" were defined as neutral molecules. All compounds also were investigated in a counterscreen for their direct effects on PP1c activity (data not shown). Unfortunately, none of the compounds encircled in Figure 6B in blue ("hits") showed I-1 P inhibitory activity when tested at different concentrations in the manually executed fluorescence assay (data not shown). Thus, at this point, no small-molecule inhibitors of the PP1c-I-1 P interaction could be identified.
Discussion
Protein phosphatases are notoriously difficult drug targets. 2 Reasons include their involvement in essentially all signaling processes and the observation that specificity is not primarily determined by phosphatase catalytic isoforms but rather their targeting to specific compartments via regulatory subunits. Modulation of PP1 regulatory subunits has become a substantial aim in many disease areas such as diabetes (PP1/hepatic glycogen-targeting subunit [GL]), hypertension (PP1/smooth muscle regulatory subunit [M110]), and Parkinson disease and drug addiction (PP1/ DARPP-32). [24] [25] [26] Recently, salubrinal and guanabenz have been identified as relatively potent inhibitors of the PP1/ growth arrest and DNA damage-inducible protein (GADD34) complex. 27, 28 These molecules target pathways involved in endoplasmic reticulum stress by disruption of the stress-induced dephosphorylation of the α-subunit of translation initiation factor 2 (eIF2α).
Our previous studies with genetically engineered mice indicated that dampening of the intracellular β-adrenergic signaling in the heart by genetic deletion of I-1 might be beneficial for chronic heart disease. 8, 11, 12 The present study established the first assay feasible for HTS for small molecules interfering with the inhibitory effect of I-1 P on PP1c. We used PKA-phosphorylated recombinant mouse I-1, recombinant rabbit PP1c, and either pNPP or DiFMUP as substrates. Both are universal phosphatase substrates and commonly used for the determination of phosphatase activities and the effect of natural toxins with the PP1c and PP2Ac inhibitory effect such as microcystin. 22, 29 The DiFMUP-based fluorescence assay was shown to be clearly superior to the pNPP assay, 500-fold more sensitive, cheap, and robust with Z′ factors (0.84 and 0.73), well above currently accepted limits. Moreover, it compared well with the gold standard radioactive assay with recombinant PP1c and [ 32 P]-labeled phosphorylase a as substrate (Fig. 5C) . The sensitivity of PP1c to inhibition by I-1 P in the DiFMUP assay was similar to values measured previously with the radioactive assay (14 nM vs. 1-2 nM 3, 21 ). The small difference may reflect normal variability or could indicate a true difference between recombinant PP1c and native PP1c used in previous studies. 6, 21 A lower sensitivity of recombinant PP1c against I-1 P (compared with fresh native PP1c) was previously described by Endo et al. 17 and is likely due to lack of metals such as Mn 2+ in the active site of the enzyme. Despite this difference, recombinant and native PP1c behaved very similar when directly compared in the DiFMUP assay, both in terms of negligible I-1 P dephosphorylation when used at a concentration of 4 mU/100 µL and sensitivity to inhibition by I-1 P (Suppl. Fig. S1 ). Rabbit PP1c was used instead of human PP1c because it is commercially available and protein sequences of rabbit and human PP1c share 100% identity (data not shown). PP1c charges from two suppliers did not differ when directly compared (data not shown).
Importantly, both nonradioactive assay formats proved useful in characterizing an I-1 nonapeptide as a novel inhibitor of PP1c-I-1 P interactions. The peptide was derived from an N-terminal region of I-1 that had been proposed previously to be involved in its interaction with PP1c. 3, 17 In contrast to a control peptide, the peptide containing the KIQF motif stimulated PP1c activity concentration-dependently when assayed together with the PP1c-I-1 P /I-1 SP complex (in both assays) and showed reasonable potency (2-30 µM depending on the assay format). The effect of I-1 SPRKIQFTV on PP1c activity was further confirmed in the radioactive phosphorylase a assay (Fig. 5c) . However, the peptides showed no significant effect on PP1c alone (not shown). These results do not formally prove but suggest that the peptide interrupted the protein-protein interaction of I-1 P with PP1c. Thus, we regard the peptide as a proof-of-principle for the validity of the assay.
The DiFMUP-based assay was shown to be suitable for an HTS format, but approximately 10% of the investigated compounds showed auto-fluorescence at a magnitude that obviated evaluation. This is a well-known problem of assays based on short-wavelength fluorescence substrates. A much lower fraction of compounds interfered by signal-quenching effects. To circumvent the interfering signals, we performed large-scaled kinetic measurements similar to our original assay format. Based on two calculated factors, gradient and signal convergence at time 0 (T = 0; Fig. 6A) , the compounds could be categorized into neutral, interferer, potential I-1, and PP1c inhibitors in one assay system. Moreover, effective compounds with simultaneous auto-fluorescence activity also could be recognized. Direct effects on PP1c were evaluated in a counterscreen. Beside these merits, a critical point of the kinetic measurements could be a relatively long read time (30 min) per plate compared with the single-point measurements. This may restrict the throughput.
In conclusion, we present a robust, sensitive, and simple phosphatase-inhibitor kinetic assay system suitable for drug discovery purposes. Putative small-molecule antagonists were identified in the primary screen phase using the methods described. However hit confirmation during secondary screens was not successful, reflecting the inherent difficulty in obtaining unequivocal data at the primary HTS. This is associated with the nature of the protein-protein interactions, which mean very few compounds would be expected to be specific hits. Nevertheless, the methodology was sound in that peptide-based compounds produced consistent results. In future studies, we intend to apply the same screening method with larger libraries, including proteinprotein interaction compounds and/or in silico screenings to improve the chances of identifying and confirming hits.
